Thank you, Arthur. My comments this afternoon will focus primarily on our non-GAAP results unless otherwise noted. Today, I'll review the financial highlights from our third quarter and first nine months 2019, as well as our outlook for the remainder of the year. Consistent with our results each of the last two quarters and our focus of continuing to generate strong EBITDA results and cash flows, our financial results in the third quarter demonstrate the achievements we continue to make in this regard. As Arthur mentioned and I'll describe further, we are accelerating some of our cost savings initiatives to ensure that we can continue to delever in 2020 and beyond. Our goal remains to continue to operate the business with above-average EBITDA margins, a consistent absolute EBITDA dollar performance and a determined focus on cash flows that we can continue to exceed our debt service obligations, allowing us to make the necessary reinvestments into the base business and pursue growth opportunities. Our neurology revenues for the third quarter and first nine months were $26.3 million and $78.7 million respectively. For the third quarter, this represents a 10% decline versus the prior year quarter. This result is below what we expected from the business, now putting us 3.2% behind year-to-date result from the prior year. While most of this can be blamed on the 450 basis point headwind created by the unforeseen Zipsor sales returns, we've described in prior quarters, we're no longer expecting to be able to deliver on our prior guidance of low-single-digit growth in our neurology revenues and now expect the full year to be between $102 million to $105 million. There are two factors driving this change. First, as Arthur mentioned, we're seeing a higher-than-expected turnover in the CSO sales force that started in our third quarter. The results in territory vacancies have made it challenging to deliver the volume growth, we've been targeting. This was the reason why we decided to terminate the CSO relationship effective at the end of this year and transition to our own full-time employees and rightsize the total field force. Second, we had expected some additional volumes for Gralise in the second half of 2019 from the execution of a midyear managed care contract with one of the top three Part D insurers. Unfortunately, Gralise was not added to their national formulary as we had expected. Any benefits we may receive from this contract will be modest as approximately one-third of this insurer's covered lives will have formulary access to Gralise. Gralise generated sales for the third quarter and nine months of $14.9 million and $46 million respectively. The year-over-year revenue growth of 2.1% and 9-month revenue growth of 6.3% was primarily due to price and a favorable mix shift towards commercial business where we recognized higher net selling prices. Prescription trends are modestly down year-over-year. However, we're encouraged by the progress we're making as we've seen sequential improvement in both prescription trends and ex-factory volumes for the second consecutive quarter. CAMBIA volumes continue to perform well with a 2.1% sequential and 3.4% year-over-year improvement per event prescription demand in the quarter. In the third quarter, CAMBIA generated sales of $8.1 million, which was down 21.5% versus the prior year. Year-to-date results were $23.7 million or a 4.3% decrease. While we saw an improvement in net revenues quarter-over-quarter, we continue to experience an unfavorable payer mix across both our commercial and government lines of business as compared to our prior year. We continue to enhance our patient access programs to ensure those patients who benefit from CAMBIA receive their prescriptions at affordable cost. While this is eating our prescription volume growth in the short term it does come at an increased cost. We expect these investments to begin to compensate for the adverse payer mix in 2020. Third quarter sales of Zipsor were $3.3 million. The quarterly results were impacted by the short data product returns issue we have experienced this year but nowhere near the extent we've previously seen. At this point we can confidently say this issue is behind us. And we've taken the necessary steps to ensure we don't see this in the future such as smaller and more frequent production lines. Year-to-date, sales for Zipsor were $9 million. If not for the abnormal returns, we would have reported approximately 4% net revenue growth for the brand this year. Zipsor prescription volumes continued to deliver. We grew 9.3% for the quarter which puts us at 13% year-to-date over the prior year. We expect to see sequential improvement in Zipsor net sales in our fourth quarter reflecting seasonality and the cessation of the returns issue. We recorded $27.3 million in GAAP commercialization agreement revenues from Collegium in the third quarter versus $31 million in the second quarter. While Collegium did report slightly lower quarterly net revenues this quarter, our change in GAAP revenues is driven more by the accounting for the royalties related to Grünenthal, the effect of which we expect to completely reverse next quarter. These royalties are contractually reimbursable by Collegium. However, we recorded the accrual for the royalty expense, which in the third quarter was $2.9 million at a contra revenue item. Per GAAP, the revenue we recorded from Collegium's reimbursement offsetting the year-to-date expense accrual will be recognized in our fourth quarter. Our non-GAAP royalty income of $31.1 million in the quarter is more reflective of the cash we received as well as the royalty calculated for the agreement with Collegium. In our fourth quarter, we expect to see this GAAP to non-GAAP difference reverse. Adjusted EBITDA was $34.3 million for the quarter, relative to the $36.4 million in the second quarter and $45 million in the prior year period. The prior year quarter included a $20 million gain on the sale of the remainder interest in our diabetes royalties to PDL. Excluding this gain, adjusted EBITDA was up 37.2% year-over-year. The strong EBITDA performance exemplifies our continued focus on operational efficiencies. Year-to-date, we recorded $107.4 million of adjusted EBITDA. As a result of our strong operating performance, we're raising our full year EBITDA guidance to $124 million to $129 million from $118 million to $128 million. There is powerful leverage to our business and the platform we've built, demonstrated this year by our ability to continue to deliver on our adjusted EBITDA targets. We've anticipated Collegium's reduced expectations for the NUCYNTA franchise in our revised guidance. The structure of that commercialization agreement was purposely designed so that our economics are minimally impacted despite fluctuations in their revenues between $180 million and $210 million in annual sales. It's important to recall that the agreement structure will affect our fourth quarter adjusted EBITDA. Year-to-date, we've recognized 65% of Collegium's reported net sales and we'll continue to recognize 65% royalties, up to $180 million in sales. Above the $180 million we will only recognize royalties at a 14% rate until Collegium achieves $210 million in sales. We actually expect a lower non-GAAP revenue, which will also lower our adjusted EBITDA relative to the first three quarters. In addition, we expect that our research and development expenses will increase in the fourth quarter to reflect investments in our CAMBIA life cycle extension and in manufacturing. In the third quarter we had a number of onetime items in our GAAP results, notably our convertible bond refinancing transaction that was completed in August, as well as the write-off of some specialized manufacturing equipment for NUCYNTA ER. Both of these items have been excluded from our adjusted EBITDA performance. The $10.1 million asset write-off appears in our SG&A on the face of our income statement. We've chosen to dispose of the equipment acquired from Janssen in 2015. We've made the decision to pursue a new manufacturing source for the product and are beginning our work to transfer production. There is no cash impact associated with this charge in the quarter. There is a minor accrual for disposal costs to be incurred in the future. In August, we exchanged $200 million in principal of our convertible notes due in September of 2021 for a combination of $120 million in principal of new 2024 convertible notes, $30 million in cash and 15.8 million shares of common stock. This reduced our total debt by $80 million and extended the maturity of a significant portion of that tranche of debt. Associated with this transaction for GAAP purposes, we recorded a gain on extinguishment of $26.4 million, representing the excess of the book carrying value of the notes over the fair value of the exchange notes. We've made tremendous progress this year reducing our overall debt balance through generation of operating cash flow and the convertible bond exchange. Entering the year, we had $627.5 million of debt all of which was due in 2021. And our gross debt leverage was 5.1 times. Today we have a total debt balance of $427.5 million, a reduction of $200 million and of which $307.5 million is due by 2021 considerably improving our liquidity. Our gross leverage ratio now sits at a reasonable 3.4 times. We'll continue to focus on cash generation, to exceed our debt service obligations. We believe we will be able to address the remainder of our 2021 maturities, through a combination of our scheduled debt amortization, reduction in cash interest payments, a potential for further exchanges, and other actions which are within our control. Also, 95% of our year-to-date 2019 total revenues are patent-protected through 2024. We believe we have considerable runway ahead of us to continue generating cash to fund business development. And pursue new growth opportunities. As mentioned earlier, we're announcing today that we're accelerating certain cost savings initiatives, which are designed to deliver $20 million in annual expense reduction, of which we expect at least $15 million will be realized in 2020. Associated with this, we expect to take a charge of approximately $4 million in our fourth quarter. This will take place at year-end. And take effect immediately. The changes will be seen in three areas, all of roughly equal impact. The first as Arthur described, will be a reduction on the size of our field force, by bringing on a portion of the CSO force. The second is, changes to our internal processes and a reduction in the use of certain outside vendors and consultants. The third will be changes to our organizational structures. I commend our operating teams for the results they've achieved to date, at reducing the overall cost base of Assertio. And making our processes more efficient and increasing our ability to make operating decisions, quicker and more proactive. These efforts we're now undertaking are further improvements, which will only make us stronger and continue our ability to deliver strong EBITDA. And make the necessary investments for the future. That concludes the financial discussion. And I'll turn the call back over to, John.
